This is an open label, phase I study assessing the safety and tolerability of a pharmaceutical formulation comprising a protein that is being developed as a treatment for acute ischemic stroke.
Eligible participants will be required to stay in the clinical unit for a total of 4 nights and 5 days.
Participants must meet the following criteria:
Male or Female between the ages of 18 and 50
BMI must be between 18 – 30 kg/m2
Medication free with no allergies to any drugs
Non-smokers
Free from any clinically significant illness or disease as determined by medical history
Remuneration is offered to eligible participants.
Click here to register for our clinical trials.
